Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes.

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas.

It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells.

The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

Nateglinide is contraindicated in patients who: A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial".